NAFLD in the absence of metabolic syndrome: Different epidemiology, pathogenetic mechanisms, risk factors for disease progression?

Seminars in Liver Disease

Volumn 32, Issue 1, 2012, Pages 14-21

  Yilmaz, Yusuf ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

hemoglobin; metabolic syndrome; nonalcoholic fatty liver disease; risk factors

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HEMOGLOBIN A; HEMOGLOBIN BETA CHAIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ALCOHOL CONSUMPTION; BLOOD PRESSURE; BLOOD VISCOSITY; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROPOIESIS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; IRON OVERLOAD; LIPID PEROXIDATION; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER FIBROSIS; LIVER ISCHEMIA; LIVER PERFUSION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FATTY LIVER; HEMOGLOBINS; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84857933945     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1306422     Document Type: Review

References (81)

1. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc: 2010; 69 2 211 220
2. Almeda-Valds P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol: 2009; 8 Suppl 1 S18 S24
3. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med: 2008; 75 10 721 728
4. Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr: 2006; 1 1 36 40
5. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep: 2008; 10 1 73 80
6. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol: 2011; 300 5 G697 G702
7. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion: 2011; 83 1-2 124 133
8. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol: 2010; 24 5 695 708
9. Lockman KA, Nyirenda MJ. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease. Curr Diabetes Rev: 2010; 6 5 341 347
10. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev: 2009; 10 4 412 419
11. Kumashiro N, Erion DM, Zhang D., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A: 2011; 108 39 16381 16385
12. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science: 2011; 332 6037 1519 1523
13. Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol: 2011; 46 3 200 215
14. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des: 2010; 16 17 1941 1951
15. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab: 2008; 19 10 371 379
16. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis: 2010; 14 4 591 604
17. Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol: 2011; 5 2 253 263
18. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis: 2010; 30 4 391 401
19. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism: 2011; 60 3 313 326
20. Aktas B, Yilmaz Y, Eren F., et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism: 2011; 60 4 544 549
21. Kukla M, Zwirska-Korczala K, Hartleb M., et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol: 2010; 45 2 235 242
22. Petta S, Camm C, Cabibi D, Di Marco V, Crax A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2011; 34 7 757 766
23. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS ONE: 2010; 5 7 e11578
24. Zimmer V, Lammert F. Genetics in liver disease: new concepts. Curr Opin Gastroenterol: 2011; 27 3 231 239
25. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res: 2011; 52 4 593 617
26. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol: 2011; 5 2 189 200
27. Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids: 2010; 82 4-6 265 271
28. Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med: 2011; 9 70
29. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol: 2010; 56 2 159 167
30. Cortez-Pinto H, Machado M. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol: 2008; 2 2 217 231
31. Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs: 2011; 16 1 121 136
32. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab: 2009; 11 3 188 195
33. Federico A, Niosi M, Vecchio Blanco CD, Loguercio C. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs: 2008; 13 1 145 158 (Pubitemid 351448707)
34. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev: 2010; 1 CD007340
35. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol: 2008; 6 12 1396 1402
36. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis: 2001; 21 1 27 41 (Pubitemid 32240484)
37. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis: 2010; 42 5 320 330
38. Green RM. NASHhepatic metabolism and not simply the metabolic syndrome. Hepatology: 2003; 38 1 14 17 (Pubitemid 36775789)
39. Adams LA, Lymp JF, St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology: 2005; 129 1 113 121 (Pubitemid 41002048)
40. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol: 2006; 290 5 G852 G858
41. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med: 1998; 15 7 539 553 (Pubitemid 28319935)
42. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs: 1999; 58 Suppl 1 7 10, discussion 75-82 (Pubitemid 129758574)
43. Grundy SM, Cleeman JI, Daniels SR., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation: 2005; 112 17 2735 2752 (Pubitemid 41532612)
44. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: 2001; 285 19 2486 2497
45. Einhorn D, Reaven GM, Cobin RH., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract: 2003; 9 3 237 252
46. Alberti KG, Zimmet P, Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndromea new worldwide definition. Lancet: 2005; 366 9491 1059 1062 (Pubitemid 41338752)
47. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia: 2005; 48 9 1684 1699 (Pubitemid 41317821)
48. Kahn R, Buse J, Ferrannini E, Stern M.; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2005; 28 9 2289 2304 (Pubitemid 41242486)
49. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res: 2007; 4 1 32 38 (Pubitemid 46649071)
50. Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia: 2005; 48 4 649 656 (Pubitemid 40591219)
51. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol: 2002; 156 11 1070 1077 (Pubitemid 35396938)
52. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP.; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation: 2004; 110 10 1251 1257 (Pubitemid 39202341)
53. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract: 2007; 77 3 471 478 (Pubitemid 47211344)
54. Marchesini G, Bugianesi E, Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology: 2003; 37 4 917 923 (Pubitemid 36397405)
55. Yilmaz Y, Senates E, Ayyildiz T., et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest: 2011; 10.1111/j.1365-2362.2011.02597.x
56. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J: 2008; 411 1 1 18 (Pubitemid 351482341)
57. Trak-Smayra V, Dargere D, Noun R., et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut: 2009; 58 6 825 832
58. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut: 2009; 58 12 1706 1707
59. Yu C, Xu C, Xu L., et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol: 2012; 56 1 241 247
60. Watanabe J, Chou KJ, Liao JC., et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem: 2007; 282 32 23698 23707 (Pubitemid 47311940)
61. Alayash AI, Patel RP, Cashon RE. Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal: 2001; 3 2 313 327 (Pubitemid 32473345)
62. Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol: 2008; 89 4 241 250 (Pubitemid 352019180)
63. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin: 2009; 33 Suppl 1 S46 S57
64. Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS ONE: 2011; 6 9 e24363
65. Chen SC, Yeh JJ, Chang MH., et al. Gender difference of alanine aminotransferase elevation may be associated with higher hemoglobin levels among male adolescents. PLoS ONE: 2010; 5 10 e13269
66. Sakugawa H, Nakayoshi T, Kobashigawa K., et al. Alanine aminotransferase elevation not associated with fatty liver is frequently seen in obese Japanese women. Eur J Clin Nutr: 2004; 58 9 1248 1252 (Pubitemid 39264022)
67. Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis: 2010; 28 1 210 213
68. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol: 2009; 8 Suppl 1 S40 S43
69. Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond): 2008; 115 1 1 12 (Pubitemid 351930788)
70. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol: 2008; 49 4 600 607
71. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med: 2010; 363 14 1341 1350
72. Carter C, McGee D, Reed D, Yano K, Stemmermann G. Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. Am Heart J: 1983; 105 4 674 679 (Pubitemid 13161934)
73. Campbell MJ, Elwood PC, Mackean J, Waters WE. Mortality, haemoglobin level and haematocrit in women. J Chronic Dis: 1985; 38 10 881 889 (Pubitemid 15233763)
74. Sorlie PD, Garcia-Palmieri MR, Costas R Jr, Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Am Heart J: 1981; 101 4 456 461 (Pubitemid 11151006)
75. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular diseasethe Framingham Study: a 34-year follow-up. Am Heart J: 1994; 127 3 674 682 (Pubitemid 24124700)
76. Smith S, Julius S, Jamerson K, Amerena J, Schork N. Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. J Hypertens: 1994; 12 4 455 462 (Pubitemid 24145399)
77. Burch GE, DePasquale NP. Hematocrit, viscosity and coronary blood flow. Dis Chest: 1965; 48 3 225 232
78. Lowe GD, Forbes CD. Platelet aggregation, haematocrit, and fibrinogen. Lancet: 1985; 1 8425 395 396 (Pubitemid 15163502)
79. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation: 1992; 86 3 803 811
80. Tong PC, Kong AP, So WY., et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. Diabetes Care: 2006; 29 11 2439 2444 (Pubitemid 44912249)
81. Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J: 2001; 142 4 657 663 (Pubitemid 32900492)